Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
Study Purpose
This phase I/II trial studies the side effects and best dose of temsirolimus when given together with sorafenib tosylate and to see how well they work in treating patients with glioblastoma that has come back. Sorafenib tosylate may stop the growth of tumor cells by blocking blood flow to the tumor. Drugs used in chemotherapy, such as temsirolimus, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Sorafenib tosylate and temsirolimus may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving sorafenib tosylate with temsirolimus may kill more tumor cells.
Recruitment Criteria
|
Accepts Healthy Volunteers
Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms |
No |
|
Study Type
An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes. Searching Both is inclusive of interventional and observational studies. |
Interventional |
| Eligible Ages | 18 Years and Over |
| Gender | All |
Inclusion Criteria:
- - Central pathology review submission; this review is mandatory prior to registration to confirm eligibility; it should be initiated as soon after surgery as possible.
- - =< 2 prior systemic chemotherapy regimens.
- - Histological confirmation of a grade 4 astrocytoma (glioblastoma) or gliosarcoma, at primary diagnosis or recurrence by World Health Organization (WHO) criteria; central pathology review is mandatory prior to study entry to confirm eligibility.
- - Evidence of tumor progression by magnetic resonance imaging (MRI) or computed tomography (CT) scan following radiation therapy (RT) or following the most recent anti-tumor therapy.
- - Bidimensionally measurable or evaluable disease by MRI or CT scan.
- - Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2.
- - >= 12 weeks since the completion of RT.
- - Fixed or decreasing dose of corticosteroids (or no corticosteroids) >= 1 week prior to registration.
- - >= 1 week from minor surgery other than venous line placement and > 3 weeks from major surgery (except for patients undergoing tumor tissue acquisition) - >= 4 weeks since prior cytotoxic chemotherapy (>= 6 weeks for nitrosoureas) - >= 2 weeks from cytostatic chemotherapy such as tamoxifen, cis-retinoic acid, or thalidomide (address questions regarding such agents to study chair) - White blood cells (WBC) >= 3,000/mm^3.
- - Absolute neutrophil count (ANC) >= 1,500/mm^3.
- - Platelet count >= 100,000/mm^3.
- - Hemoglobin (Hgb) >= 10 gm/dL.
- - Total bilirubin =< 1.5 x upper limit of normal (ULN) - Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =< 2.5 x ULN.
- - Creatinine =< 2.0 x ULN.
- - Serum cholesterol =< 350 mg/dL.
- - Serum triglycerides =< 400 mg/dL.
- - Willingness to provide the biologic specimens as required by the protocol; (please
note that the willingness to participate pertains only to the patient and does not
factor in the institution?s ability to participate in any part of the translational
component)
Exclusion Criteria:
- Prior intratumoral chemotherapy (e.g., Gliadel or IL13-PE38QQR), stereotactic radiosurgery, or interstitial brachytherapy unless there is a separate lesion on MRI which is not part of the previous treatment field or there is proof of recurrent disease based on biopsy, MRI spectroscopy, or positron emission tomography (PET) scan.
- - Prior CCI-779, sorafenib, or other agents specifically targeting mammalian target of rapamycin (mTOR) or raf; patients receiving prior agents inhibiting VEGF or VEGF receptor (R) (prior anti-VEGF group) are eligible but: 1) must be at least four weeks from last treatment with the agent(s); and 2) must have recovered from any clinically relevant toxicities attributable to this agent(s) - Evidence of bleeding diathesis or coagulopathy.
- - Note: Patients on prophylactic anticoagulation therapy (e.g., low-dose warfarin) are eligible provided their coagulation parameter levels are as follows: prothrombin time (International Normalized Ratio [INR] of prothrombin time) < 1.1 x institutional upper limit of normal.
- - Note: Patients on full-dose anticoagulants (e.g., warfarin) are eligible provided that both of the following criteria are met: a) the patient has an in-range INR (usually between 2 and 3) on a stable dose of oral anticoagulant or on a stable dose of low molecular weight heparin, and b) the patient has no active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices) - International normalized ration (INR) > 1.5 (unless the patient is on full-dose warfarin) - Receiving enzyme-inducing antiepileptic drugs (EIAEDs; e.g., phenytoin, fosphenytoin, carbamazepine, phenobarbital, or primidone) or any other potent cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) inducer, such as rifampin or St. John?s wort.
- - Any condition (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease) that impairs their ability to swallow pills.
- - Hypertension with systolic blood pressure of > 140 mmHg or diastolic pressure > 90 mmHg; however, patients with well-controlled hypertension are eligible.
- - Uncontrolled infection.
- - Pregnant women.
- - Nursing women.
- - Men or women of childbearing potential who are unwilling to employ adequate contraception.
- - Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
- - Known hypersensitivity to any of the components of CCI-779 or sorafenib.
- - Other active malignancy.
- - Uncontrolled intercurrent illness, including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, psychiatric illness/social situation that would preclude study compliance with study requirements.
- - Immunocompromised patients (other than that related to the use of corticosteroids) including patients known to be human immunodeficiency virus (HIV) positive; HIV-positive patients on combination antiretroviral therapy are ineligible.
- - Receiving any investigational agents other than CCI-779 and sorafenib.
Trial Details
|
Trial ID:
This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries. |
NCT00329719 |
|
Phase
Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans. Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data. Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use. |
Phase 1/Phase 2 |
|
Lead Sponsor
The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data. |
National Cancer Institute (NCI) |
|
Principal Investigator
The person who is responsible for the scientific and technical direction of the entire clinical study. |
Kurt Jaeckle |
| Principal Investigator Affiliation | Alliance for Clinical Trials in Oncology |
|
Agency Class
Category of organization(s) involved as sponsor (and collaborator) supporting the trial. |
NIH |
| Overall Status | Completed |
| Countries | United States |
|
Conditions
The disease, disorder, syndrome, illness, or injury that is being studied. |
Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Neoplasm |
Primary Objective
- - Phase I (closed to accrual as of 01/11/2008): To establish a maximum tolerable dose of temsirolimus in combination with sorafenib in patients with recurrent glioblastoma not receiving enzyme-inducing anticonvulsants (EIACs).
- - Phase I (closed to accrual as of 01/11/2008): I.
- II. To assess the evidence of antitumor activity.
- I. To assess the safety and toxicities of temsirolimus and sorafenib in the above-noted patient populations.
Arms
Experimental: Group I (sorafenib tosylate, temsirolimus)
Patients receive sorafenib tosylate and temsirolimus as in Phase I.
Experimental: Group II (sorafenib tosylate, temsirolimus, surgery)
Patients receive sorafenib tosylate PO BID on days 1-8 and temsirolimus IV over 30 minutes on day 1. Patients undergo surgery on day 8. After recovering from surgery, patients receive sorafenib tosylate and temsirolimus as in Phase I.
Experimental: Group III (sorafenib tosylate, temsirolimus, anti-VEGF)
Patients who have received prior anti-VEGF therapy and are not undergoing surgery receive sorafenib tosylate and temsirolimus as in Phase I.
Interventions
Procedure: - Conventional Surgery
Undergo surgery
Other: - Laboratory Biomarker Analysis
Correlative studies
Drug: - Sorafenib Tosylate
Given PO
Drug: - Temsirolimus
Given IV
Contact a Trial Team
If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.
Status
Address
Providence Alaska Medical Center
Anchorage, Alaska, 99508
Status
Address
Mayo Clinic in Arizona
Scottsdale, Arizona, 85259
Status
Address
Smilow Cancer Hospital Care Center at Saint Francis
Hartford, Connecticut, 06105
Status
Address
Mayo Clinic in Florida
Jacksonville, Florida, 32224-9980
Status
Address
Saint Alphonsus Cancer Care Center-Boise
Boise, Idaho, 83706
Status
Address
Rush - Copley Medical Center
Aurora, Illinois, 60504
Status
Address
Saint Joseph Medical Center
Bloomington, Illinois, 61701
Status
Address
Illinois CancerCare-Bloomington
Bloomington, Illinois, 61704
Status
Address
Graham Hospital Association
Canton, Illinois, 61520
Status
Address
Illinois CancerCare-Canton
Canton, Illinois, 61520
Status
Address
Illinois CancerCare-Carthage
Carthage, Illinois, 62321
Status
Address
Memorial Hospital
Carthage, Illinois, 62321
Status
Address
Rush University Medical Center
Chicago, Illinois, 60612
Status
Address
Heartland Cancer Research NCORP
Decatur, Illinois, 62526
Status
Address
Saint Anthony Memorial Hospital
Effingham, Illinois, 62401
Status
Address
Eureka Hospital
Eureka, Illinois, 61530
Status
Address
Illinois CancerCare-Eureka
Eureka, Illinois, 61530
Status
Address
Galesburg Cottage Hospital
Galesburg, Illinois, 61401
Status
Address
Illinois CancerCare-Galesburg
Galesburg, Illinois, 61401
Status
Address
Illinois CancerCare-Havana
Havana, Illinois, 62644
Status
Address
Mason District Hospital
Havana, Illinois, 62644
Status
Address
Hopedale Medical Complex - Hospital
Hopedale, Illinois, 61747
Status
Address
Joliet Oncology-Hematology Associates Limited
Joliet, Illinois, 60435
Status
Address
Illinois CancerCare-Kewanee Clinic
Kewanee, Illinois, 61443
Status
Address
Kewanee Hospital
Kewanee, Illinois, 61443
Status
Address
Illinois CancerCare-Macomb
Macomb, Illinois, 61455
Status
Address
Mcdonough District Hospital
Macomb, Illinois, 61455
Status
Address
Holy Family Medical Center
Monmouth, Illinois, 61462
Status
Address
Illinois CancerCare-Monmouth
Monmouth, Illinois, 61462
Status
Address
Bromenn Regional Medical Center
Normal, Illinois, 61761
Status
Address
Community Cancer Center Foundation
Normal, Illinois, 61761
Status
Address
Illinois CancerCare-Community Cancer Center
Normal, Illinois, 61761
Status
Address
Illinois CancerCare-Ottawa Clinic
Ottawa, Illinois, 61350
Status
Address
Ottawa Regional Hospital and Healthcare Center
Ottawa, Illinois, 61350
Status
Address
Illinois CancerCare-Pekin
Pekin, Illinois, 61554
Status
Address
OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center
Pekin, Illinois, 61554
Status
Address
Pekin Hospital
Pekin, Illinois, 61554
Status
Address
Methodist Medical Center of Illinois
Peoria, Illinois, 61603
Status
Address
Proctor Hospital
Peoria, Illinois, 61614
Status
Address
Illinois CancerCare-Peoria
Peoria, Illinois, 61615
Status
Address
OSF Saint Francis Medical Center
Peoria, Illinois, 61637
Status
Address
Illinois CancerCare-Peru
Peru, Illinois, 61354
Status
Address
Illinois Valley Hospital
Peru, Illinois, 61354
Status
Address
Illinois CancerCare-Princeton
Princeton, Illinois, 61356
Status
Address
Perry Memorial Hospital
Princeton, Illinois, 61356
Status
Address
Illinois CancerCare-Spring Valley
Spring Valley, Illinois, 61362
Status
Address
Saint Margaret's Hospital
Spring Valley, Illinois, 61362
Status
Address
Carle Cancer Center
Urbana, Illinois, 61801
Status
Address
The Carle Foundation Hospital
Urbana, Illinois, 61801
Status
Address
Franciscan Saint Anthony Health-Michigan City
Michigan City, Indiana, 46360
Status
Address
McFarland Clinic PC-William R Bliss Cancer Center
Ames, Iowa, 50010
Status
Address
Mercy Hospital
Cedar Rapids, Iowa, 52403
Status
Address
Oncology Associates at Mercy Medical Center
Cedar Rapids, Iowa, 52403
Status
Address
Medical Oncology and Hematology Associates-West Des Moines
Clive, Iowa, 50325
Status
Address
Mercy Capitol
Des Moines, Iowa, 50307
Status
Address
Iowa Methodist Medical Center
Des Moines, Iowa, 50309
Status
Address
Iowa-Wide Oncology Research Coalition NCORP
Des Moines, Iowa, 50309
Status
Address
Medical Oncology and Hematology Associates-Des Moines
Des Moines, Iowa, 50309
Status
Address
Medical Oncology and Hematology Associates-Laurel
Des Moines, Iowa, 50314
Status
Address
Mercy Medical Center - Des Moines
Des Moines, Iowa, 50314
Status
Address
Iowa Lutheran Hospital
Des Moines, Iowa, 50316
Status
Address
Mercy Medical Center - North Iowa
Mason City, Iowa, 50401
Status
Address
Siouxland Regional Cancer Center
Sioux City, Iowa, 51101
Status
Address
Mercy Medical Center-Sioux City
Sioux City, Iowa, 51104
Status
Address
Saint Luke's Regional Medical Center
Sioux City, Iowa, 51104
Status
Address
Hospital District Sixth of Harper County
Anthony, Kansas, 67003
Status
Address
Cancer Center of Kansas - Chanute
Chanute, Kansas, 66720
Status
Address
Cancer Center of Kansas - Dodge City
Dodge City, Kansas, 67801
Status
Address
Cancer Center of Kansas - El Dorado
El Dorado, Kansas, 67042
Status
Address
Cancer Center of Kansas - Fort Scott
Fort Scott, Kansas, 66701
Status
Address
Cancer Center of Kansas-Independence
Independence, Kansas, 67301
Status
Address
Cancer Center of Kansas-Kingman
Kingman, Kansas, 67068
Status
Address
Lawrence Memorial Hospital
Lawrence, Kansas, 66044
Status
Address
Southwest Medical Center
Liberal, Kansas, 67901
Status
Address
Cancer Center of Kansas-Liberal
Liberal, Kansas, 67905
Status
Address
Cancer Center of Kansas - McPherson
McPherson, Kansas, 67460
Status
Address
Cancer Center of Kansas - Newton
Newton, Kansas, 67114
Status
Address
Cancer Center of Kansas - Parsons
Parsons, Kansas, 67357
Status
Address
Cancer Center of Kansas - Pratt
Pratt, Kansas, 67124
Status
Address
Cancer Center of Kansas - Salina
Salina, Kansas, 67401
Status
Address
Cancer Center of Kansas - Wellington
Wellington, Kansas, 67152
Status
Address
Associates In Womens Health
Wichita, Kansas, 67208
Status
Address
Cancer Center of Kansas-Wichita Medical Arts Tower
Wichita, Kansas, 67208
Status
Address
Cancer Center of Kansas - Wichita
Wichita, Kansas, 67214
Status
Address
Via Christi Regional Medical Center
Wichita, Kansas, 67214
Status
Address
Wichita NCI Community Oncology Research Program
Wichita, Kansas, 67214
Status
Address
Cancer Center of Kansas - Winfield
Winfield, Kansas, 67156
Status
Address
Michigan Cancer Research Consortium NCORP
Ann Arbor, Michigan, 48106
Status
Address
Saint Joseph Mercy Hospital
Ann Arbor, Michigan, 48106
Status
Address
Bronson Battle Creek
Battle Creek, Michigan, 49017
Status
Address
Spectrum Health Big Rapids Hospital
Big Rapids, Michigan, 49307
Status
Address
Beaumont Hospital-Dearborn
Dearborn, Michigan, 48124
Status
Address
Saint John Hospital and Medical Center
Detroit, Michigan, 48236
Status
Address
Green Bay Oncology - Escanaba
Escanaba, Michigan, 49829
Status
Address
Genesys Hurley Cancer Institute
Flint, Michigan, 48503
Status
Address
Hurley Medical Center
Flint, Michigan, 48503
Status
Address
Genesys Regional Medical Center-West Flint Campus
Flint, Michigan, 48532
Status
Address
Cancer Research Consortium of West Michigan NCORP
Grand Rapids, Michigan, 49503
Status
Address
Mercy Health Saint Mary's
Grand Rapids, Michigan, 49503
Status
Address
Spectrum Health at Butterworth Campus
Grand Rapids, Michigan, 49503
Status
Address
Green Bay Oncology - Iron Mountain
Iron Mountain, Michigan, 49801
Status
Address
Allegiance Health
Jackson, Michigan, 49201
Status
Address
Sparrow Hospital
Lansing, Michigan, 48912
Status
Address
Saint Mary Mercy Hospital
Livonia, Michigan, 48154
Status
Address
Mercy Health Mercy Campus
Muskegon, Michigan, 49444
Status
Address
Saint Joseph Mercy Oakland
Pontiac, Michigan, 48341
Status
Address
Lake Huron Medical Center
Port Huron, Michigan, 48060
Status
Address
Saint Mary's of Michigan
Saginaw, Michigan, 48601
Status
Address
Munson Medical Center
Traverse City, Michigan, 49684
Status
Address
Saint John Macomb-Oakland Hospital
Warren, Michigan, 48093
Status
Address
Metro Health Hospital
Wyoming, Michigan, 49519
Status
Address
Medini, Eitan MD (UIA Investigator)
Alexandria, Minnesota, 56308
Status
Address
Sanford Clinic North-Bemidgi
Bemidji, Minnesota, 56601
Status
Address
Fairview Ridges Hospital
Burnsville, Minnesota, 55337
Status
Address
Mercy Hospital
Coon Rapids, Minnesota, 55433
Status
Address
Essentia Health Cancer Center
Duluth, Minnesota, 55805
Status
Address
Essentia Health Saint Mary's Medical Center
Duluth, Minnesota, 55805
Status
Address
Miller-Dwan Hospital
Duluth, Minnesota, 55805
Status
Address
Fairview-Southdale Hospital
Edina, Minnesota, 55435
Status
Address
Etzell, Paul S MD (UIA Investigator)
Fergus Falls, Minnesota, 56537
Status
Address
Lake Region Healthcare Corporation-Cancer Care
Fergus Falls, Minnesota, 56537
Status
Address
Swenson, Wade II, MD (UIA Investigator)
Fergus Falls, Minnesota, 56537
Status
Address
Unity Hospital
Fridley, Minnesota, 55432
Status
Address
Hutchinson Area Health Care
Hutchinson, Minnesota, 55350
Status
Address
Meeker County Memorial Hospital
Litchfield, Minnesota, 55355
Status
Address
Minnesota Oncology Hematology PA-Maplewood
Maplewood, Minnesota, 55109
Status
Address
Saint John's Hospital - Healtheast
Maplewood, Minnesota, 55109
Status
Address
Abbott-Northwestern Hospital
Minneapolis, Minnesota, 55407
Status
Address
Minnesota Cooperative Group Outreach Program
Minneapolis, Minnesota, 55407
Status
Address
Virginia Piper Cancer Institute
Minneapolis, Minnesota, 55407
Status
Address
Hennepin County Medical Center
Minneapolis, Minnesota, 55415
Status
Address
New Ulm Medical Center
New Ulm, Minnesota, 56073
Status
Address
North Memorial Medical Health Center
Robbinsdale, Minnesota, 55422
Status
Address
Mayo Clinic
Rochester, Minnesota, 55905
Status
Address
Coborn Cancer Center at Saint Cloud Hospital
Saint Cloud, Minnesota, 56303
Status
Address
Saint Cloud Hospital
Saint Cloud, Minnesota, 56303
Status
Address
Metro Minnesota Community Oncology Research Consortium
Saint Louis Park, Minnesota, 55416
Status
Address
Park Nicollet Clinic - Saint Louis Park
Saint Louis Park, Minnesota, 55416
Status
Address
Regions Hospital
Saint Paul, Minnesota, 55101
Status
Address
Saint Joseph's Hospital - Healtheast
Saint Paul, Minnesota, 55102
Status
Address
United Hospital
Saint Paul, Minnesota, 55102
Status
Address
Saint Francis Regional Medical Center
Shakopee, Minnesota, 55379
Status
Address
Lakeview Hospital
Stillwater, Minnesota, 55082
Status
Address
Ridgeview Medical Center
Waconia, Minnesota, 55387
Status
Address
Rice Memorial Hospital
Willmar, Minnesota, 56201
Status
Address
Minnesota Oncology Hematology PA-Woodbury
Woodbury, Minnesota, 55125
Status
Address
Woodwinds Health Campus
Woodbury, Minnesota, 55125
Status
Address
Nebraska Cancer Research Center
Lincoln, Nebraska, 68510
Status
Address
Missouri Valley Cancer Consortium
Omaha, Nebraska, 68106
Status
Address
Alegent Health Immanuel Medical Center
Omaha, Nebraska, 68122
Status
Address
Alegent Health Bergan Mercy Medical Center
Omaha, Nebraska, 68124
Status
Address
Alegent Health Lakeside Hospital
Omaha, Nebraska, 68130
Status
Address
Creighton University Medical Center
Omaha, Nebraska, 68131
Status
Address
Rutherford Hospital
Rutherfordton, North Carolina, 28139
Status
Address
Southeast Clinical Oncology Research (SCOR) Consortium NCORP
Winston-Salem, North Carolina, 27104
Status
Address
Mid Dakota Clinic
Bismarck, North Dakota, 58501
Status
Address
Saint Alexius Medical Center
Bismarck, North Dakota, 58501
Status
Address
Sanford Bismarck Medical Center
Bismarck, North Dakota, 58501
Status
Address
Roger Maris Cancer Center
Fargo, North Dakota, 58122
Status
Address
Sanford Broadway Medical Center
Fargo, North Dakota, 58122
Status
Address
Sanford Clinic North-Fargo
Fargo, North Dakota, 58122
Status
Address
Altru Cancer Center
Grand Forks, North Dakota, 58201
Status
Address
Lehigh Valley Hospital-Cedar Crest
Allentown, Pennsylvania, 18103
Status
Address
Lehigh Valley Hospital - Muhlenberg
Bethlehem, Pennsylvania, 18017
Status
Address
Geisinger Medical Center
Danville, Pennsylvania, 17822
Status
Address
Geisinger Medical Center-Cancer Center Hazleton
Hazleton, Pennsylvania, 18201
Status
Address
Geisinger Medical Group
State College, Pennsylvania, 16801
Status
Address
Geisinger Wyoming Valley/Henry Cancer Center
Wilkes-Barre, Pennsylvania, 18711
Status
Address
AnMed Health Cancer Center
Anderson, South Carolina, 29621
Status
Address
AnMed Health Hospital
Anderson, South Carolina, 29621
Status
Address
Saint Francis Hospital
Greenville, South Carolina, 29601
Status
Address
Spartanburg Medical Center
Spartanburg, South Carolina, 29303
Status
Address
Rapid City Regional Hospital
Rapid City, South Dakota, 57701
Status
Address
Sanford Cancer Center Oncology Clinic
Sioux Falls, South Dakota, 57104
Status
Address
Avera Cancer Institute
Sioux Falls, South Dakota, 57105
Status
Address
Avera McKennan Hospital and University Health Center
Sioux Falls, South Dakota, 57105
Status
Address
Medical X-Ray Center
Sioux Falls, South Dakota, 57105
Status
Address
Sanford USD Medical Center - Sioux Falls
Sioux Falls, South Dakota, 57117-5134
Status
Address
University of Virginia Cancer Center
Charlottesville, Virginia, 22908
Status
Address
Virginia Commonwealth University/Massey Cancer Center
Richmond, Virginia, 23298
Status
Address
Virginia Mason Medical Center
Seattle, Washington, 98101
Status
Address
Green Bay Oncology at Saint Vincent Hospital
Green Bay, Wisconsin, 54301-3526
Status
Address
Saint Vincent Hospital Cancer Center Green Bay
Green Bay, Wisconsin, 54301
Status
Address
Green Bay Oncology Limited at Saint Mary's Hospital
Green Bay, Wisconsin, 54303
Status
Address
Saint Vincent Hospital Cancer Center at Saint Mary's
Green Bay, Wisconsin, 54303
Status
Address
Holy Family Memorial Hospital
Manitowoc, Wisconsin, 54221
Status
Address
Bay Area Medical Center
Marinette, Wisconsin, 54143
Status
Address
Green Bay Oncology - Oconto Falls
Oconto Falls, Wisconsin, 54154
Status
Address
HSHS Saint Nicholas Hospital
Sheboygan, Wisconsin, 53081
Status
Address
Green Bay Oncology - Sturgeon Bay
Sturgeon Bay, Wisconsin, 54235
